Oligomerix to Present at Upcoming Life Sciences Conferences
WHITE PLAINS, N.Y.--(BUSINESS WIRE)--Oligomerix, Inc., a privately held company pioneering the development of small molecule therapeutics targeting tau for rare neurodegenerative and Alzheimer’s diseases, announced that the company will be presenting at several upcoming conferences in February.
Details for each presentation can be found below.
7th Annual LSX World Congress Virtual
Dates: February 1-5, 2021
https://www.lsxleaders.com/lsx-world-congress
Video on-demand
Westchester County Association’s All Access Healthcare: Spotlight on Westchester's BioScience Ecosystem
Date: February 11, 2021, 9:00 am to 10:00 am ET
https://www.westchester.org/events/all-access-healthcare-spotlight-on-westchesters-bioscience-ecosystem/
BIO CEO & Investor Digital Conference
Dates: February 16-18, 2021
https://www.bio.org/events/bio-ceo-investor-digital-conference/sessions/765607
Video on-demand
National Institutes of Health Longevity Innovations & Neurodegeneration Company Showcase (LINCS)
Date: February 24, 2021, 12:30 pm to 1:30 pm ET
Session Title: Alzheimer’s Disease Therapeutics Company Showcase & Alzheimer’s Disease Therapeutics
https://www.cvent.com/c/express/aef768d7-0c3d-4e87-8b56-7bd653dc5edd
About Oligomerix’s Lead Program
Oligomerix’s lead candidate is a small molecule inhibitor of tau self-association that targets the beginning of the tau aggregation cascade and its progression. The activity of the drug translated from in vitro and cell assays to animal studies, validating the company’s screening approach (Journal of Alzheimer’s Disease, 2020) for Alzheimer’s disease and rare tauopathies. The lead compound is advancing through preclinical studies, and the start of clinical studies is being planned for 2022. Accompanying novel biomarkers are in the research phase.
About Oligomerix, Inc.
Oligomerix is an emerging biotechnology company focused on developing disease-modifying therapeutics for neurodegenerative diseases characterized by aberrant tau protein ranging from rare tauopathies such as progressive supranuclear palsy and frontotemporal dementia to Alzheimer’s disease. The company’s drug discovery platform has identified a pipeline of novel small molecule inhibitors, with preclinical IND-enabling studies in progress for the lead program. Oligomerix’s small molecule approach blocks the formation of all tau aggregates by targeting tau self-association, the first step of the tau aggregation cascade, whereas other companies have focused on targeting large tau aggregates formed downstream. Oligomerix is headquartered at the Westchester Park Center in White Plains, New York and has lab facilities at the Ullmann Research Center for Health Sciences within the Albert Einstein College of Medicine.
Oligomerix is seeking strategic partners to support the acceleration and advancement of these important programs. For more information about Oligomerix, please visit http://www.oligomerix.com.
Contacts
Company Contacts
Jack Pasini
Chief Commercial Officer
917-912-4088
jpasini@oligomerix.com
James Moe, Ph.D., MBA
President and CEO
212-568-0365
jmoe@oligomerix.com
Media Contacts
Michelle Linn
Bioscribe
774-696-3803
michelle@bioscribe.com
Editor Details
-
Company:
- Businesswire
